TIANTAN BIO (600161.SS)
- Previous Close
19.16 - Open
19.18 - Bid 19.20 x --
- Ask 19.21 x --
- Day's Range
19.11 - 19.25 - 52 Week Range
18.88 - 27.60 - Volume
15,258,859 - Avg. Volume
21,229,432 - Market Cap (intraday)
37.985B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
25.96 - EPS (TTM)
0.74 - Earnings Date Apr 26, 2025
- Forward Dividend & Yield 0.15 (0.78%)
- Ex-Dividend Date Jun 20, 2024
- 1y Target Est
--
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. Beijing Tiantan Biological Products Co., Ltd. was founded in 1966 and is headquartered in Beijing, China.
www.tiantanbio.comRecent News: 600161.SS
View MorePerformance Overview: 600161.SS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600161.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600161.SS
View MoreValuation Measures
Market Cap
37.89B
Enterprise Value
35.74B
Trailing P/E
25.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.25
Price/Book (mrq)
3.33
Enterprise Value/Revenue
5.83
Enterprise Value/EBITDA
14.62
Financial Highlights
Profitability and Income Statement
Profit Margin
24.10%
Return on Assets (ttm)
9.58%
Return on Equity (ttm)
14.38%
Revenue (ttm)
6.13B
Net Income Avi to Common (ttm)
1.48B
Diluted EPS (ttm)
0.74
Balance Sheet and Cash Flow
Total Cash (mrq)
2.28B
Total Debt/Equity (mrq)
0.87%
Levered Free Cash Flow (ttm)
-1.96B